Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Rachel Wittenberg"'
Autor:
Rachel Tanner, Andrew D. White, Charelle Boot, Claudia C. Sombroek, Matthew K. O’Shea, Daniel Wright, Emily Hoogkamer, Julia Bitencourt, Stephanie A. Harris, Charlotte Sarfas, Rachel Wittenberg, Iman Satti, Helen A. Fletcher, Frank A. W. Verreck, Sally A. Sharpe, Helen McShane
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Abstract We present a non-human primate mycobacterial growth inhibition assay (MGIA) using in vitro blood or cell co-culture with the aim of refining and expediting early tuberculosis vaccine testing. We have taken steps to optimise the assay using c
Externí odkaz:
https://doaj.org/article/68af0e0e83b24984a10595f180e34dba
Autor:
Rachel Tanner, Emily Hoogkamer, Julia Bitencourt, Andrew White, Charelle Boot, Claudia C. Sombroek, Stephanie A. Harris, Matthew K. O'Shea, Daniel Wright, Rachel Wittenberg, Charlotte Sarfas, Iman Satti, Frank A.W. Verreck, Sally A. Sharpe, Helen A. Fletcher, Helen McShane
Publikováno v:
F1000Research, Vol 10 (2021)
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulen
Externí odkaz:
https://doaj.org/article/f4d160f312314877839761de896f12a2
Autor:
Rachel Tanner, Emily Hoogkamer, Julia Bitencourt, Andrew White, Charelle Boot, Claudia C. Sombroek, Stephanie A. Harris, Matthew K. O'Shea, Daniel Wright, Rachel Wittenberg, Charlotte Sarfas, Iman Satti, Frank A.W. Verreck, Sally A. Sharpe, Helen A. Fletcher, Helen McShane
Publikováno v:
F1000Research, Vol 10 (2021)
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulen
Externí odkaz:
https://doaj.org/article/8d457b8383a642419000e0f51934d0e4
Autor:
Rachel Tanner, Iman Satti, Stephanie A. Harris, Matthew K. O'Shea, Deniz Cizmeci, Daniel O'Connor, Agnieszka Chomka, Magali Matsumiya, Rachel Wittenberg, Angela M. Minassian, Joel Meyer, Helen A. Fletcher, Helen McShane
Publikováno v:
Frontiers in Immunology, Vol 10 (2020)
Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of
Externí odkaz:
https://doaj.org/article/3a79f6ae1f1441c1bc01dc2dd53f6d80
Autor:
Simon J. Waddell, C B Fotso, Naomi Bull, Rachel Wittenberg, Hill Avs., Daire Cantillon, M Madhavan, Nicola Ternette, Annalisa Nicastri, Nawamin Pinpathomrat, Helen McShane, Elena Stylianou, Julius Muller, Paulo Bettencourt, Philip D. Charles
Publikováno v:
npj Vaccines, Vol 5, Iss 1, Pp 1-14 (2020)
NPJ Vaccines
NPJ Vaccines
Mycobacterium tuberculosis (M.tb) is responsible for more deaths globally than any other pathogen. The only available vaccine, bacillus Calmette-Guérin (BCG), has variable efficacy throughout the world. A more effective vaccine is urgently needed. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90d354060f4bbeac8a4d020d2945f54
http://link.springer.com/article/10.1038/s41541-019-0148-y
http://link.springer.com/article/10.1038/s41541-019-0148-y
Autor:
F Perrin, H Bettinson, M Riste, Daniel B. Wright, Stephanie A. Harris, Catherine Cosgrove, Alison M. Lawrie, Samantha Vermaak, Paul Moss, Marc Lipman, Fergus V. Gleeson, Christopher P. Conlon, Helen McShane, Jennifer L. Marshall, R Powell Doherty, Iman Satti, Rachel Wittenberg, Martin Dedicoat, Morven Wilkie, R Lopez Ramon
Publikováno v:
Vaccines
Volume 9
Issue 4
Vaccines, Vol 9, Iss 396, p 396 (2021)
Volume 9
Issue 4
Vaccines, Vol 9, Iss 396, p 396 (2021)
The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8572cfa07e14d4e5e36473d0dd38436
http://europepmc.org/articles/PMC8073411
http://europepmc.org/articles/PMC8073411
Autor:
Rachel, Tanner, Emily, Hoogkamer, Julia, Bitencourt, Andrew, White, Charelle, Boot, Claudia C, Sombroek, Stephanie A, Harris, Matthew K, O'Shea, Daniel, Wright, Rachel, Wittenberg, Charlotte, Sarfas, Iman, Satti, Frank A W, Verreck, Sally A, Sharpe, Helen A, Fletcher, Helen, McShane
Publikováno v:
F1000Research
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d5d6e84b1ac06b4dd26fe60af550d8b
https://pubmed.ncbi.nlm.nih.gov/33976866
https://pubmed.ncbi.nlm.nih.gov/33976866
Autor:
E Hoogkamer, Andrew White, Helen A. Fletcher, Daniel B. Wright, Verreck Faw., Stephanie A. Harris, Charlotte Sarfas, Claudia C. Sombroek, J Bitencourt, Charelle Boot, Rachel Tanner, Sally Sharpe, Helen McShane, Matthew K. O'Shea, Iman Satti, Rachel Wittenberg
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
NPJ Vaccines
NPJ Vaccines
We present a non-human primate mycobacterial growth inhibition assay (MGIA) using in vitro blood or cell co-culture with the aim of refining and expediting early tuberculosis vaccine testing. We have taken steps to optimise the assay using cryopreser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::782fb2ef066acb216357698e58030129
https://doi.org/10.1038/s41541-020-00263-7
https://doi.org/10.1038/s41541-020-00263-7
Autor:
Rachel, Tanner, Iman, Satti, Stephanie A, Harris, Matthew K, O'Shea, Deniz, Cizmeci, Daniel, O'Connor, Agnieszka, Chomka, Magali, Matsumiya, Rachel, Wittenberg, Angela M, Minassian, Joel, Meyer, Helen A, Fletcher, Helen, McShane
Publikováno v:
Frontiers in Immunology
Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::096bd227aa0b2adb9999e5c8c997c8be
https://pubmed.ncbi.nlm.nih.gov/31998295
https://pubmed.ncbi.nlm.nih.gov/31998295
Autor:
Helen A. Fletcher, Rachel Wittenberg, Charlotte Sarfas, Claudia C. Sombroek, Charelle Boot, Emily Hoogkamer, Daniel B. Wright, Stephanie A. Harris, Frank A. W. Verreck, Iman Satti, Julia Bitencourt, Rachel Tanner, Matthew K. O'Shea, Helen McShane, Andrew White, Sally Sharpe
Publikováno v:
F1000Research. 10:257
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c91bf1133f4e2c485fb7e7ed96fcfcdc
https://doi.org/10.12688/f1000research.51640.1
https://doi.org/10.12688/f1000research.51640.1